Hepatitis C Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Nave Not Been Treated

By Ana Balkandjieva

16 September 2021

6 December 2018, Paris, France, New York, NY— People living with hepatitis C, access to medicines activists, and the medical community around the world “mark” the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), launched by Gilead Sciences. A global hepatitis C coalition has released a fact sheet revealing treatment barriers that resulted in only 1.85 million of the 71 million people worldwide who need treatment, receiving Gilead’s sofosbuvir-based drugs, largely due to pricing, patents, and registration delays.

Continue reading here.

Related materials

Treatment for Hepatitis C: The Patent System is Standing in the Way of Access to Medicine

Following the appeal filed by AIDES, Médecins du Monde and Médecins sans Frontières, the European Patent Office has decided to uphold the patent of sofosbuvir, hindering the launch of an affordable generic version of the drug in Europe. More

10 October 2023Advocate Campaigns Liberate Generics!

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More

10 August 2022Advocate Campaigns Liberate Generics!

Sofosbuvir Case in Brazil

Sofosbuvir case in Brazil is well analysed in a new publication ’Access to Medicines and Vaccines: Implementing Flexibilities Under Intellectual Property Law’. More

26 April 2022Advocate Campaigns Liberate Generics!

Gilead’s Claim That Generic Purchase of Sofosbuvir Would Lead to Patent Infringement in Brazil Dismissed

Gilead claims there is a patent infringement by two generic producers and directly asked to block any eventual commercialization of sofosbuvir products by these producers in Brazil. More

11 April 2022Advocate Campaigns Liberate Generics!

Activists Demand Affordable Hepatitis C Treatment

Activists’ demonstrations demanding affordable hepatitis C treatment and universal access to generic medicines everywhere. More

21 September 2021Advocate Campaigns Liberate Generics!

First Hepatitis C Treatment Developed Through South-South Cooperation Registered in Malaysia

New treatment combination for hepatitis C virus is an additional affordable option for millions still waiting for access to lifesaving treatments in middle-income countries. More

21 September 2021Advocate Campaigns Liberate Generics!

Doctors of the World Opposes the Patent on Sofosbuvir

Hepatitis C: scourge, remedy and scandal

This is the first time in Europe that a medical NGO uses this juridical tool to improve patients access to treatment. More

16 September 2021Advocate Campaigns Liberate Generics!

Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain

Myths and facts

Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More

16 September 2021Advocate Campaigns Liberate Generics!

About the Campaign

Generic competition to accelerate the number of people who start treatment is stalled due to Gilead’s, AbbVie’s, and their sub-licensees’ delay or failure to register their drugs. More

15 September 2021Advocate Campaigns Liberate Generics!

APN+ Joins MTAAG+ in Congratulating Malaysia on Sofosbuvir Compulsory License

Compulsory license ends Gilead’s dangerous games with lives of hepatitis C patients in Malaysia; Result of hard fought efforts of community-based groups, NGOs and treatment providers. More

15 September 2021Advocate Campaigns Liberate Generics!